Evotec SE (EVT HM) stock market data APIs
€2.9998
0.01(0.3%)
as of October 2, 2026
Try our APIs with
free plan!
Evotec SE Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for EVT.HM.
Prev. Close
2.9998
Open
3.004
High
3.0126
Low
2.9977
52 wk Range
2.732-7.492
Market Cap
7 158 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Evotec SE data using free add-ons & libraries
Get Evotec SE Fundamental Data
Evotec SE Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Evotec SE News
New
4BIO Capital leads €40 Million ($45M) seed financing of Aptadir Therapeutics to advance first-in-class demethylating medicines
4Bio Capital Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditions Seed led by 4BIO Capital with follow-on participation from the company's original pre-seed inve...
Evotec Announces Chief Scientific Officer Transition
Dr. Cord Dohrmann to step down as of September 30, 2026 Search ongoing for a successor HAMBURG, Germany, Sept. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today a...
APTADIR RAISES A €40M ($45M) SEED FINANCING TO ADVANCE FIRST-IN-CLASS DEMETHYLATING MEDICINES
Giovanni Amabile, Founder and CEOGiovanni Amabile, Founder and CEO of Aptadir Therapeutics Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditions Seed is led by 4B...
Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave
Company Logo Pharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support targeted therapies. Dublin, Sept. 24,...
Get Evotec SE fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.